Chronic Kidney Disease

Sparsentan decreased proteinuria by nearly 50% in patients with IgA nephropathy, which may slow kidney function decline.

Letermovir is the only drug approved for prophylaxis of cytomegalovirus (CMV) infection for patients who are CMV-seropositive and have received an allogeneic HSCT.

Patients with heart failure are at a significant risk of cardiorenal diseases, highlighting the need for improved treatments and cost management.

The knowledge of clinical pharmacists can help protect kidney function and prevent the development of acute kidney injury in ICU patients.

Daprodustat (Jesduvroq, GSK) is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor to gain approval in the United States.

Providers must carefully prescribe, monitor, and adjust renally relevant drug lists in patients with chronic kidney disease to prevent progression.

A community-based multidisciplinary team can have a significant impact addressing health disparities and diabetes management.

In a phase 3 trial, empagliflozin significantly reduced the risk of kidney disease progression or cardiovascular death in adults with chronic kidney disease by 28% compared with placebo.

The oral SGLT2 inhibitor has been shown to reduce blood sugar and improve glycemic control as an adjunct to diet and exercise.

Data from a randomized clinical trial supports previous clinical findings on SGLT2 inhibitors and their ability to slow the progression of chronic kidney disease.

The report highlights the growth of personalized medicines with improved efficacy for rare, previously untreatable diseases.

The protein, called suPAR, has long been known to be a biomarker for poor outcomes and disease progression in both kidney disease and cardiovascular disease.

Investigators hope findings of study in mice help improve treatment for individuals with acute kidney injury.

Age was a contributing factor of chronic kidney disease and albuminuria in patients with type 1 and type 2 diabetes.

A randomized study of renin-angiotensin system inhibitors in advanced chronic kidney disease found that patients who continued receiving therapy had similar outcomes to those who discontinued treatment.

Dapagliflozin (Farxiga) found effective in lowering the risk of hospitalization for patients with chronic kidney disease, with or without a diagnosis of type 2 diabetes, and increased the number of days alive and out of the hospital.

Atrasentan has been found to lower albuminuria, which correlates with reductions in low-density lipoprotein cholesterol and triglycerides.

Inhibiting the lipid kinase VPS34 may improve the treatment of diseases such as diabetes and kidney cancer.

Pharmacists play a significant role in the comprehensive management of this condition through education, intervention, and monitoring.

Dapagliflozin and standard of care found to slow the decline in kidney function and lower the incidence of kidney failure.

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor being evaluated for the treatment of anemia of chronic kidney disease in adult patients on and not on dialysis.

Active patient care with chronic kidney disease may provide enormous benefits for patients, the economy, and society.

Next-generation research shows that targeting specific Kir channels, which regulate salt reabsorption in the kidneys, could improve diuretic function in kidney patients.

Researchers outline new findings about the connection between hyperkalemia and renin-angiotensin-aldosterone system inhibitors during a session at ASN Kidney Week.

Applying the principles of precision medicine to peritoneal dialysis could improve the flexibility and personalization of care for dialysis patients.

Daniel Weiner, MD, MS, associate professor at Tufts University, discusses effective treatment approaches for diabetic kidney disease at ASN Kidney Week.

It may be worth considering the pathophysiology and vascular complications of chemotherapy, especially among patients who are already hypertensive.

The drug is a selective, nonsteroidal mineralocorticoid receptor antagonist found to also protect against COVID-19 and pneumonia-related adverse events in patients with diabetes.

Pharmacy Times will be covering the American Society of Nephrology (ASN) Kidney Week, which will be gathering more than 10,000 professionals working on kidney health in Orlando, Florida.

The estimation of glomerular filtration rate based on cystatin C could provide a more robust prediction of cardiovascular disease and mortality in patients.